Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study

BACKGROUND: In Australia, prescribing restrictions limit access to internationally recommended second‐line therapies such as rituximab and thrombopoietin agonists (TPO‐A) (eltrombopag and romiplostim). Subsequent lines of therapy include an array of immunosuppressive and immune‐modulating agents dir...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Adam, Cashion, Catelyn, Ali, Fariya, Haran, Harini, Biswas, Raaj K., Chen, Vivien, Crowther, Helen, Curnow, Jennifer, Deakin, Elyssa, Tan, Chee‐Wee, Tan, Yi Ling, Vanlint, Andrew, Ward, Christopher M., Bird, Robert, Rabbolini, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483174/
https://www.ncbi.nlm.nih.gov/pubmed/36186101
http://dx.doi.org/10.1002/rth2.12792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483174/
https://www.ncbi.nlm.nih.gov/pubmed/36186101
http://dx.doi.org/10.1002/rth2.12792

Ejemplares similares